Towards the sustainable discovery and development of new antibiotics

  • An ever-increasing demand for novel antimicrobials to treat life-threatening infections caused by the global spread of multidrug-resistant bacterial pathogens stands in stark contrast to the current level of investment in their development, particularly in the fields of natural-product-derived and synthetic small molecules. New agents displaying innovative chemistry and modes of action are desperately needed worldwide to tackle the public health menace posed by antimicrobial resistance. Here, our consortium presents a strategic blueprint to substantially improve our ability to discover and develop new antibiotics. We propose both short-term and long-term solutions to overcome the most urgent limitations in the various sectors of research and funding, aiming to bridge the gap between academic, industrial and political stakeholders, and to unite interdisciplinary expertise in order to efficiently fuel the translational pipeline for the benefit of future generations.

Download full text files

Export metadata

Metadaten
Author:Marcus Miethke, Marco Pieroni, Karl Tilmann Weber, Mark Brönstrup, Peter Hammann, Ludovic Halby, Paola B. Arimondo, Philippe Glaser, Bertrand Aigle, Helge Björn BodeORCiDGND, Rui Moreira, Yanyan Li, Andriy Luzhetskyy, Marnix H. Medema, Jean-Luc Pernodet, Marc Stadler, José Rubén Tormo, Olga Genilloud, Andrew W. Truman, Kira J. Weissman, Eriko Takano, Stefano Sabatini, Evi Stegmann, Heike Brötz, Wolfgang Wohlleben, Myriam Seemann, Martin Empting, Anna K. H. Hirsch, Brigitta Loretz, Claus-Michael Lehr, Alexander Titz, Jennifer Herrmann, Timo Jäger, Silke Alt, Thomas Hesterkamp, Mathias Winterhalter, Andrea Schiefer, Kenneth Pfarr, Achim Hoerauf, Heather Graz, Michael Graz, Mika Lindvall, Savithri Ramurthy, Anders Karlén, Maarten van Dongen, Hrvoje Petkovic, Andreas Keller, Frédéric Peyrane, Stefano Donadio, Laurent Fraisse, Laura J. V. Piddock, Ian H. Gilbert, Heinz E. Moser, Rolf MüllerORCiDGND
URN:urn:nbn:de:hebis:30:3-632543
DOI:https://doi.org/10.1038/s41570-021-00313-1
ISSN:2397-3358
Parent Title (English):Nature reviews. Chemistry
Publisher:Macmillan Publishers Limited, part of Springer Nature
Place of publication:Basingstoke
Document Type:Article
Language:English
Date of Publication (online):2021/08/19
Date of first Publication:2021/08/19
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2022/05/18
Tag:Business strategy in drug development; Drug therapy
Volume:5
Page Number:24
First Page:726
Last Page:749
Note:
Coordination of the IRAADD consortium is funded by the JPIAMR-VRI, including the publication of this article. The project on PqsR pathoblocker development acknowledges funding through the German Center for Infection Research (DZIF; projects TTU09.908 and TTU09.916), the Helmholtz Association (Helmholtz Validation Fund) and additional contributions by the associated academic institutes (HZI and HIPS). The development of chelocardins is supported by the DZIF (TTU09.814/09.821), the Helmholtz Innovation Fund (Pre-4D), by the Slovenian Research Agency, ARRS, grant no. J4-8226, and in collaboration with AciesBio, Slovenia. The corallopyronin project is funded by the DZIF (TTU09.807/09.816, TTU09.914), the German Federal Ministry of Education and Research (BMBF), the federal state of North Rhine-Westphalia (EFRE.NRW) and EU Horizon 2020. Eriko Takano was funded by the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 720793 “TOPCAPI: Thoroughly Optimised Production Chassis for Advanced Pharmaceutical Ingredients”.
HeBIS-PPN:496021095
Institutes:Biowissenschaften
Dewey Decimal Classification:5 Naturwissenschaften und Mathematik / 57 Biowissenschaften; Biologie / 570 Biowissenschaften; Biologie
6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (German):License LogoCreative Commons - Namensnennung 4.0

OPUS4 Logo